---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-23-001809"
form_type: "8-K"
ticker: "CMMB"
cik: "0001534248"
company_name: "Chemomab Therapeutics Ltd."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:04:47.839339+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Chemomab Q1 net loss $8.8M; cash $32.8M; CM-101 Phase 2 NASH trial meets safety endpoint

## Summary
- Net loss of $8.8M ($0.04 per share) vs $5.1M in Q1 2022; R&D expenses rose to $6.9M from $2.7M.
- Cash, equivalents and short-term deposits $32.8M at March 31, 2023, down from $39.9M at Dec 31, 2022; runway extended through H1 2024.
- CM-101 Phase 2 NASH liver fibrosis trial met primary safety endpoint; showed positive activity on fibrotic and inflammatory biomarkers.
- FDA cleared IND for CM-101 Phase 2 systemic sclerosis trial; initial U.S. sites expected to open mid-2023.
- Phase 2 PSC trial advancing with higher dose cohort; top-line data from double-blind portion expected H2 2024.

## SEC filing metadata
- accession: 0001178913-23-001809
- form_type: 8-K
- ticker: CMMB
- cik: 0001534248
- company_name: Chemomab Therapeutics Ltd.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534248/000117891323001809/0001178913-23-001809-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534248/000117891323001809/zk2329704.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-23-001809
- JSON: https://secwatch.observer/filing/0001178913-23-001809.json
- Plain text: https://secwatch.observer/filing/0001178913-23-001809.txt

## Key facts
- Earnings Releases
  Chemomab Therapeutics Ltd. reported first quarter ended March 31, 2023 results: net income $8.8 million, EPS approximately $0.04 per basic and diluted ordinary share.
  - Period: first quarter ended March 31, 2023
  - Net income: $8.8 million
  - EPS: approximately $0.04 per basic and diluted ordinary share
  - Result: reported results
  source text: Net loss was $8.8 million, or a net loss of approximately $0.04 per basic and diluted ordinary share for the first quarter of 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534248/000117891323001809/0001178913-23-001809-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.